MLLT3 Nucleic Acid Expansion of Human Hematopoietic Stem Cells

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods face challenges in maintaining and expanding engraftable human hematopoietic stem cells (HSCs) in culture and generating them from pluripotent stem cells, as the key machinery governing self-renewal and engraftment remains elusive.

Innovation Solution

The use of MLLT3 nucleic acids or CDK9 kinase inhibitors to promote the expansion and self-renewal of hematopoietic stem cells, involving methods such as introducing MLLT3 into cells, incubating with CDK9 kinase inhibitors, and exposing cells to differentiation agents or stromal cells to enhance culture viability and transplantation ability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of stationary object

If conventional culture methods are used to maintain human HSCs, then the cells can be kept in culture for a limited time, but the duration and number of generations are insufficient for clinical applications

Engineering Contradiction:

Improveculture maintenance timeVSAvoidcell expansion efficiency

Core Design Contradiction:

Duration of action of stationary objectVSProductivity

Solution Approach 1:

The invention changes the chemical parameters of the culture system by introducing MLLT3 nucleic acids or CDK9 kinase inhibitors to modify the biological behavior of HSCs, enabling extended culture maintenance and improved self-renewal capabilities

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

MLLT3 acts as an intermediary molecule that mediates between the culture conditions and HSC self-renewal pathways, while CDK9 kinase inhibitors serve as intermediaries to modulate transcriptional regulation and promote HSC expansion

Inventive Principle:

Principle #24Intermediary (Mediator)

2Quantity of substance

If HSCs are expanded in culture to increase cell numbers, then more cells are available for transplantation, but the engraftment ability and self-renewal capability may be compromised

Engineering Contradiction:

Improvenumber of HSCsVSAvoidengraftment ability

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

By changing the molecular parameters through MLLT3 introduction or CDK9 inhibition, the invention maintains HSC quality attributes (engraftment ability and self-renewal capability) while achieving quantitative expansion suitable for clinical transplantation

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The system employs feedback mechanisms where MLLT3 overexpression or CDK9 inhibition continuously monitors and maintains HSC self-renewal markers and engraftment potential during expansion, ensuring that quality is preserved alongside quantity increase

Inventive Principle:

Principle #23Feedback

3Loss of information

If the key machinery governing HSC self-renewal is not understood, then mechanistic insights are lacking, but this limits the ability to optimize culture and generation methods

Engineering Contradiction:

Improvemechanistic understandingVSAvoidculture optimization

Core Design Contradiction:

Loss of informationVSEase of manufacture

Solution Approach 1:

The invention allows the HSC system to self-regulate through endogenous pathways (MLLT3 overexpression or CDK9 inhibition) that naturally promote self-renewal and engraftment, reducing the need for external mechanistic knowledge while achieving optimized culture outcomes

Inventive Principle:

Principle #25Self-service

Data Source

PatentUS11845959B2Identification of factor that promotes human HSC self-renewal

Publication Date: 2023.12.19 RGT UNIV OF CALIFORNIA

AI summary

Transient MLLT3 overexpression in culture may be used to expand human HSCs in vitro, and thereby improve the efficiency and safety of HSC transplantation.